Tourmaline Bio Highlights Cardiovascular Inflammation Focus And Announces Key Clinical And Strategic Updates At Investor Day; Phase 2 TRANQUILITY Trial Surpasses Enrollment Target, With 143 Total Patients Enrolled
Tourmaline Bio Highlights Cardiovascular Inflammation Focus And Announces Key Clinical And Strategic Updates At Investor Day; Phase 2 TRANQUILITY Trial Surpasses Enrollment Target, With 143 Total Patients Enrolled
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today is hosting its Investor Day, beginning at 10 a.m. ET, during which it will outline progress across its pipeline and provide updates on its strategic priorities.– Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of 2025 –
– 第二階段TRanquility試驗超過了招募目標，共招募了143名患者；預計在2025年第二季度發佈初步數據 –
– Deepak L. Bhatt, MD, MPH, MBA and Dipender Gill, MD, PhD join Cardiovascular Scientific Advisory Board –
– Deepak L. Bhatt博士、公共衛生碩士、工商管理碩士和Dipender Gill博士、哲學博士加入心血管科學顧問委員會 –
– Company nominates abdominal aortic aneurysm as second cardiovascular indication for pacibekitug, expanding development for inflammation-driven cardiovascular disease –
– 公司提名腹主動脈瘤作爲pacibekitug的第二個心血管適應症，擴展針對炎症驅動的心血管疾病的發展 –
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today is hosting its Investor Day, beginning at 10 a.m. ET, during which it will outline progress across its pipeline and provide updates on its strategic priorities.
紐約，2024年12月10日（GLOBE NEWSWIRE）-- Tourmaline Bio, Inc.（Tourmaline）（納斯達克：TRML）是一家臨床後期生物技術公司，正在開發變革性藥物，以顯著改善生活的影響患者的免疫和炎症疾病的患者的生活，今天將舉行投資者日活動，活動於東部時間上午10點開始，期間將概述其管道的進展並提供其戰略優先事項的更新。
